Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The State Health Plan's decision to end coverage of certain weight-loss prescription drugs has produced an unlikely and ...

A weight loss and diabetes drug remains in a shortage but for the last month, San Ysidro Pharmacy has been supplying patients ...

Danish drugmaker Novo Nordisk will invest 864 million reais ($158.2 million) to revamp a plant in Brazil responsible for ...

Ozempic and similar drugs are often effective because they produce feelings of satisfaction, in line with the NBC theory of ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

NBC 7 dives deep into the explosive popularity of the medications and explores both the life-changing benefits and the ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Dr. Christopher McGowan, MD, an obesity medicine specialist at True You Weight Loss, says the decision to drink on Ozempic is ...

The FDA has approved Wegovy for weight loss. It’s a higher-dose version of the same drug in Ozempic with the same active ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” ...